期刊文献+

免疫检查点抑制剂在食管癌治疗中的研究进展 被引量:3

Advances in the treatment of immune checkpoint inhibitors for esophageal cancer
原文传递
导出
摘要 免疫治疗是一种新兴的食管癌治疗方法,且越来越受到人们的重视。已经完成的和正在进行中的食管癌免疫治疗临床试验均肯定了免疫检查点抑制剂在食管癌治疗中的巨大潜力。将免疫疗法与现有的或者新的治疗模式相结合,以及甄别可能从免疫治疗中获益的人群将是未来研究的重点。 As a new therapeutic strategy for esophageal cancer,immunotherapy has attracted more and more attention.The completed and ongoing clinical trials of immunotherapy for esophageal cancer confirm the great potential of immune checkpoint inhibitors in esophageal cancer.Future research will focus on the combination of immunotherapy with existing or new therapeutic modalities and the identification of populations likely to benefit from immunotherapy.
作者 童欣 邢力刚 Tong Xin;Xing Ligang(Department of Radiation Oncology,Shandong Cancer Hospital Affiliated to Shandong First Medical University,Jinan 250117,China;Department of Radiation Oncology,Zibo Central Hospital,Zibo 255000,China)
出处 《中国医师杂志》 CAS 2022年第1期142-145,共4页 Journal of Chinese Physician
基金 国家自然科学基金(81572970) 国家重点研发项目(2018YFC1313200)。
关键词 食管肿瘤 免疫检查点抑制剂 生物标记 Esophageal neoplasms Immune checkpoint inhibitors Biomarkers
  • 相关文献

参考文献9

二级参考文献32

  • 1Tai X, Van Laethem F, Pobezinsky L, et al. Basis of CTLA-4 func-tion in regulatory and conventional CD4 + T cells [ J ]. Blood, 2012,119(22); 5155 -5163.
  • 2Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects onthe response of T cells to stimulation[ J]. J Immunol, 2011,187(7):3459 -3465.
  • 3Lu Y, Schneider H, Rudd CE. Murine regulatory T cells differ fromconventional T cells in resisting the CTLA-4 reversal of TCR stop-signal[J]. Blood, 2012, 120(23) : 4560 -4570.
  • 4Sellebjerg F, Krakauer M,Khademi M, et al. FOXP3, CBLB andITCH gene expression and cytotoxic T lymphocyte antigen 4 expressionon CD4 + CD25hlgh T cells in multiple sclerosis[ J]. Clin Exp Immunol,2012,170(2); 149 -155.
  • 5Youlin K, Li Z,Xiaodong W, et al. Combination immunotherapy with4-1BBL and CTLA-4 blockade for the treatment of prostate cancer[ J/OA]. Clin Dev Immunol, 2012,2012 : 439235.
  • 6Waitz R, Solomon SB, Petre EN, et ai. Potent induction of tumorimmunity by combining tumor cryoablation with anti-CTLA-4 therapy[J]. Cancer Res, 2012,72(2) : 430 - 439.
  • 7Ribas A. Clinical development of the anti-CTLA-4 antibody tremeli-mumab[ J]. Semin Oncol, 2010,37(5): 450 -454.
  • 8Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibitsin trans[J]. J Immunol, 2012, 189(3) : 1123 -1127.
  • 9Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy:immune monitoring during clinical development of a novel immunotherapy[J]. Semin Oncol, 2010, 37(5) : 473 -484.
  • 10Hirota K, Martin B, Veldhoen M. Development, regulation andfunctional capacities of Thl7 cells[ J]. Semin Immunopathol, 2010,32(1) : 3-16.

共引文献3540

同被引文献25

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部